Claims for Patent: 6,780,614

Summary for Patent: 6,780,614

Title:	Modified factor VIII cDNA and its use for the production of factor VIII
Abstract:	A modified Factor VIII cDNA is disclosed wherein the B-domain of the wild type factor cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in two locations of the Factor VIII cDNA and as a promoter a cDNA is used which is suitable for the expression in hematopoietic cell lines and specifically in platelets.
Inventor(s):	Negrier; Claude (Irigny, FR), Plantier; Jean-Luc (Gringy, FR)
Assignee:	Aventis Behring GmbH (Marburg, DE)
Application Number:	10/067,894
Patent Claims:	1. A modified Factor VIII cDNA, comprising: a wild-type factor VIII cDNA, at least one intron, which has been inserted into at least one location of said wild-type factor VIII cDNA, wherein said at least one intron is not a factor VIII intron; and a promoter which targets the expression of said modified factor VIII cDNA to hematopoietic cells. 2. Modified Factor VIII cDNA as claimed in claim 1, wherein the B-domain of the wild-type factor VIII cDNA has been deleted. 3. Modified Factor VIII cDNA as claimed in claim 1, wherein said at least one intron is factor IX truncated intron 1. 4. Modified Factor VIII cDNA as claimed in claim 1, wherein said promoter is the human platelet glycoprotein IIb promoter. 5. Modified Factor VIII cDNA as claimed in claim 1, wherein said hematopoietic cells are megakaryocytes. 6. Modified Factor VIII cDNA as claimed in claim 1, wherein said at least one intron has been inserted into the wild-type factor VIII cDNA at the original positions of intron 1 and intron 13 of the genomic Factor VIII DNA. 7. A process for the production of Factor VIII, comprising: culturing a cell line under conditions suitable to produce a polypeptide encoded by the modified Factor VIII cDNA as claimed in claim 1; and recovering said polypeptide from the cell culture medium. 8. Process as claimed in claim 7, wherein the production of Factor VIII is stimulated by an inducer. 9. Process as claimed in claim 8, wherein said inducer is phorbol-12-myristate-13-acetate. 10. Process as claimed in claim 7, wherein said cell lint is human erythroleukemia (HEL) or Dami.

Details for Patent 6,780,614

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-02-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-02-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-02-09